Repeat angioplasty tied to further heart problems
Posted on: Friday, 7 October 2005, 09:15 CDT
NEW YORK (Reuters Health) - Patients who've already undergone angioplasty to open a blocked heart vessel and have to have a repeat angioplasty are at increased risk for problems such as death or heart attack, researchers report in the American Journal of Cardiology.
Because patients with a prior angioplasty are often excluded from clinical trials, little information is available on the long-term outcome of repeat angioplasty, senior researcher Dr. Sheldon Goldberg of Hahnemann University, Philadelphia and colleagues note.
To investigate further, the researchers used data from patients who underwent angioplasty while taking part in a drug study. In all, 7065 subjects had not had a previous angioplasty, 1281 had had a previous angioplasty of the blockage now being targeted and 1408 had had a previous angioplasty of a different blockage.
At 1 month after angioplasty, there were no significant differences between the groups in the rate of major adverse heart events, including death, heart attack and the need for further operations.
However, by 9 months, 34 percent of patients who underwent angioplasty again for the same blockage had experienced an adverse event compared with 19 percent of patients with no prior angioplasty. For patients with previous angioplasty of a different blockage, the corresponding proportion was 24 percent.
These findings have "reconfirmed the need for the development and trial of new methods to improve the outcomes of" patients undergoing repeat angioplasty.
SOURCE: American Journal of Cardiology, September 15, 2005.
Source: REUTERS
Related Articles
- Improving Treatment Of Patients With Heart Attack
- Crowded Emergency Clinics Pose Greater Risks For Patients With Heart Attacks
- Studies Indicate Exercise Training Could Provide Some Benefit For Patients With Heart Failure
- Emergency Treatment Strategies, Better Communication Among Health Care Workers Reduce Heart Attack Patient Deaths by 19 Percent, Says AHJ Published Study
- Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
- Lipitor 80 Mg Provided Sustained Risk Reduction of Cardiovascular Events in Patients With Heart Disease During the Five-Year TNT Trial
- Lipitor 80 Mg Reduced the Risk of Heart Attack and Stroke in Patients With Heart Disease, Type 2 Diabetes and Chronic Kidney Disease
- CoGenesys Initiates Phase 1-2 Clinical Trial of Cardeva in Patients With Heart Failure
- US patients with heart failure have better short-term survival rates than Canadian patients
- Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia With Darbepoetin Alfa in Patients With Heart Failure to Reduce Mortality and Hospitalization
 |
 |
User Comments (0)
RSS Feeds